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Abstract: 
 
The extracellular module of SPARC/osteonectin binds to vascular endothelial growth factor 
(VEGF) and inhibits VEGF-stimulated proliferation of endothelial cells. In an attempt to identify 
the binding site for SPARC on VEGF, we hypothesized that this binding site could overlap at 
least partially the binding site of VEGF receptor 1 (VEGFR-1), as SPARC acts by preventing 
VEGF-induced phosphorylation of VEGFR-1. To this end, a docking simulation was carried out 
using a predictive docking tool to obtain modeled structures of the VEGF–SPARC complex. The 
predicted structure of VEGF–SPARC complex indicates that the extracellular domain of SPARC 
interacts with the VEGFR-1 binding site of VEGF, and is consistent with known biochemical 
data. Following molecular dynamics refinement, side-chain interactions at the protein interface 
were identified that were predicted to contribute substantially to the free energy of binding. 
These provide a detailed prediction of key amino acid side-chain interactions at the protein–
protein interface. To validate the model further, the identified interactions will be used for 
designing mutagenesis studies to investigate their effect on binding activity. This model of the 
VEGF–SPARC complex should provide a basis for future studies aimed at identifying inhibitors 
of VEGF-induced angiogenesis. 
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Article: 
 
1. Introduction 
 
Angiogenesis, the process of new capillary blood vessel growth from pre-existing vasculature, is 
a necessary physiological process in growth and development as well as in wound healing. 
Under normal circumstances angiogenesis occurs as a highly ordered series of events, spreading 
the vascular network only to the extent required by the demands of growing tissues [1]. 
However, in spite of the tight regulation, angiogenesis can occur not only in normal development 
and physiological processes but also in pathological processes such as tumor growth and 
metastasis [2]. The role of angiogenesis in tumor progression has been well established as a 
critical step in the transition of tumors from a dormant state to a malignant state through the 
supply of oxygen and nutrients to the proliferating cells [3], [4]. Many positively and negatively 
acting factors influence angiogenesis, which is a complex multi-component process involving the 
coordinated action of many growth factors and their receptors, cytokines, proteases, extracellular 
matrix proteins and adhesion molecules [5], [6]. 
 
Abnormal blood vessel growth in the eye is a leading cause for catastrophic loss of vision and 
extensive research has been done to understand the basic, underlying mechanisms of ocular 
angiogenesis [7], [8]. Vascular endothelial growth factor (VEGF)-related family of angiogenic 
factors are believed to play a central role in ocular angiogenesis as they regulate a wide variety 
of endothelial cell functions including cell survival, migration, differentiation and vascular 
permeability. Tumor cells typically induce new blood vessel growth by up-regulating growth 
factors such as VEGF, thereby overwhelming the effect of natural angiogenesis 
inhibitors [9], [10], [11]. The abnormal levels of VEGF causes proliferation of vessels into the 
retina leading to loss of vision [12], [13], [14]. Conventional treatment methods have met with 
limited success and inhibition of growth factor-induced new vessel formation and targeting of 
pathological vessels seem to be the best choice for treating angiogenesis-related ocular 
diseases [15], [16]. 
 
1.1. VEGF and SPARC in angiogenesis 
 
VEGF, which is upregulated in many different tumor types, is the most well characterized 
angiogenic and vascular permeability enhancing factor. It is a critical regulator of both 
physiological and tumor angiogenesis [17], [18], and exerts its function by interacting with two 
high affinity tyrosine kinase receptors; fms-like tyrosine kinase (Flt-1/VEGFR-1) and the kinase 
insert domain-containing receptor (KDR/VEGFR-2) (Fig. 1). Although these receptors are 
homologous and share architectural similarity they are significantly different in their functional 
properties [19], [20], [21], [22]. As a result, the action of VEGF and the function it mediates 
depends on the site of its expression, the type of receptors present and the signals they 
initiate [23]. Normally a physiological angiogenic balance is maintained, with the endogenous 
inhibitors of angiogenesis countering the effect of proangiogenic molecules. The interactions and 
delicate balance between the different angiogenic and angiostatic factors are critical for 
regulating and treating angiogenesis [24], [25]. 
 
The glycoprotein SPARC (Secreted Protein Acidic and Rich in Cysteine) has been found to act 
as an angiogenesis inhibitor by regulating the activities of growth factors like VEGF and platelet-
derived growth factor (PDGF) [26], [27], [28], [29]. SPARC is a Ca2+-binding, multifunctional 
glycoprotein belonging to the class of matrix-associated factors that mediate cell-matrix 
interactions. The primary structure of SPARC contains four unique domains with distinct 
functional activities; it binds Ca2+ at both the amino- and carboxyl-terminal domains. It has been 
shown to be involved in the regulation of important physiological processes through the 
modulation of cell-matrix and cell-growth factor interactions [30], [31]. Specific peptide regions 
have been identified in the protein that inhibit cellular proliferation and regulate the migration of 
endothelial cells. Recent studies have shown that SPARC binds to VEGF and inhibits VEGF-
stimulated proliferation of endothelial cells [32]. It is our hypothesis that this binding site could 
overlap at least partially with the binding site of VEGFR-1, as SPARC acts by preventing 
VEGF-induced phosphorylation of VEGFR-1. In order to understand the basis for the 
multifunctional role of SPARC [33], [34], [35], further knowledge regarding its interaction with 
growth factors, especially VEGF, is important. 
 
 
Fig. 1. Schematic representation of VEGF receptors and ligands. The Flt-1 gene encodes both 
the full length receptor (Flt-1/VEGFR-1) and a soluble form (sFlt-1/sVEGFR-1). sFlt-1 is an 
endogenous inhibitor of VEGF, as it tightly binds VEGF with the same affinity as the full length 
receptor suppressing its angiogenic activity. The angiogenic activity of VEGF is due to its 
binding to VEGFR-1 and VEGFR-2. 
 
Despite the available individual structural information regarding VEGF and SPARC, the atomic 
details of their complex structure and the exact structural domains that mediate their interactions 
and subsequent biological effects still remain unclear. In the present study, molecular modeling 
and protein–protein docking simulations have been carried out towards the twin goals of 
predicting the structure of the complex and identifying specific residues involved in the 
interaction. The resulting model will enable a better understanding of the role of this pair of 
proteins in angiogenesis, and ultimately assist in the design of molecules that can inhibit the 
effect of VEGF and thereby prevent the abnormal growth of new blood vessels. 
 
1.2. Predictive docking 
 
The growing number of individual structures in the crystallographic databases and the relatively 
small number of solved complexes has made predictive docking an important theoretical 
method [36]. Protein–protein complexes are especially important since these reactions are 
biologically abundant in nature and it would be desirable to understand them in detail. It has 
been estimated that 70% of proteins function through multiprotein complexes in yeast, although 
the number of interactions in humans is difficult to estimate [37]. Because of the inherent 
difficulty in obtaining crystal structures of protein complexes, computational docking techniques 
are proving to be an essential tool for predicting the structures of such protein complexes. 
Docking strategies usually rely on a two-stage approach: first, to generate a set of possible 
orientations of the two docked proteins and then score them in a way that the native complex will 
be ranked highly. In this study, the predictive docking tool FTDock was used to perform the 
docking simulations and predict the correct binding geometry (Fig. 2). FTDock and RPScore are 
available as part of the 3D-Dock suite from the Biomolecular modeling laboratory [38], [39]. In 
this study, docking is used in concert with experimental data including site-directed mutagenesis 
to identify the correct complex structure. The extensive rigid-body docking and the use of 
structural and biochemical data to filter the results, is expected to produce a reasonable model of 
the complex. The final complex structure is then studied to analyze the intermolecular contacts 
and to identify specific residue level interactions between the proteins. The results will be used to 
direct further mutagenesis studies to investigate their effects on binding activity. The goal of our 
work is to create a detailed model of the complex and offer a structural interpretation for the 
available experimental data. 
 
 
Fig. 2. Flow diagram outlining the protein–protein docking procedure. 
 
2. Methods 
 
2.1. Protein–protein docking 
 
There are several programs available for protein–protein docking that attempt to predict the 
structure of docked complexes when the coordinates of the components are known [36]. Most of 
the algorithms are based on rigid-body docking methods, in which the larger protein is kept fixed 
and the smaller protein is rotated and translated to find the best geometric fit. In this study, 
FTDock 2.0 was selected for performing the docking simulations as it uses Fourier transform to 
rapidly evaluate the shape complementarities and also it has various post-docking processing 
methods to score the resultant complexes, including scoring based on electrostatics and 
experimental data. The program has good predictive ability, as the root mean standard distance 
of the obtained complexes can be within 1.0 Å from known crystal structures for cases where 
biological information is available [40]. The primary advantage over other programs is that 
FTDock allows filtering of thousands of docked complexes to a manageable extent based on 
available biochemical information. 
 
The individual starting structures for the docking were obtained from the PDB database [41]: the 
structure of VEGF bound to the second domain of Flt-1 receptor (PDB code: 1FLT) and the 
structure of SPARC (PDB code: 1BMO), both with resolutions of 3.0 Å or better obtained by X-
ray diffraction. Starting from the known crystal structures, the end groups and disordered 
residues on both the proteins were first fixed using the Biopolymer module in Sybyl 7.0 [42]. 
The subsequent structure of SPARC was docked on to VEGF after removing the Flt-1 receptors 
from the starting structure. Before docking, the coordinates of proteins were preprocessed to 
remove hydrogen atoms and alternative atom records. Each molecule was digitized onto a 
274 × 274 × 274 grid with a 0.7 Å grid unit and the surface thickness was set to 1.3 Å. During 
the docking simulation the larger of the two molecules, SPARC was held static and VEGF was 
translated and rotated with respect to SPARC to explore all possible orientations. The rotational 
degrees of freedom were explored by rotating the VEGF molecule in 12° angle step size and 
three rotations at each step were retained. The shape complementarity of the two molecules was 
evaluated from the overlap of the two grid functions. The docking run, which results in 10,000 
docked complexes, was performed with the inclusion of electrostatic scoring for excluding false 
positive complexes. All the docking simulations presented in this study were performed on an 
IBM-p655 cluster comprised of 32 processors. However, the FTDock program available from the 
developers is not parallelized for multiple processors and therefore the capability of the resources 
used did not reflect on the computational time taken for the simulation. 
 
2.2. Rescoring of complexes 
 
The subsequent step to docking was to reduce the number of complexes in the list that need to be 
considered in order to select the complex that will be closest to the true structure. The complexes 
obtained from the initial docking run were ranked based on the surface complementarity score 
for each of the complex structure. The complexes were rescored using RPScore, which was 
available as part of the 3D-Dock suite. The output from the docking run was sorted and ranked 
based on this alternative ranking, using the residue–residue pair potential scores for the complex 
structures. This scoring scheme based on evidence from actual protein interfaces is defined as the 
log fraction of the actual frequency and the expected frequency of occurrence, and the value of 
the score for each pair is a measure of the likelihood that the particular pair occurs and thus helps 
to quantify the probability of a complex's existence [39]. 
 
2.3. Filtering using experimental data 
 
Biochemical data was used to further filter the docking results, using the residues on the surface 
of the interacting proteins as candidates. The results obtained from RPScore were filtered based 
on the experimental information that SPARC and the peptide 4.2 from the extra cellular region of 
SPARC bind to VEGF and inhibit VEGF-induced proliferation of endothelial cells. Receptor 
activation studies have also shown that SPARC could prevent VEGF-induced phosphorylation of 
VEGFR-1, by selectively blocking the activity of this receptor [32]. These data suggest that the 
peptide 4.2 (aa 254–274) [29], [30] corresponding to the C-terminal region of SPARC should be 
in proximity to the receptor binding face of VEGF, which is primarily composed of acidic 
residues (aa 63–67) and some basic residues (aa 82–86) which mediate interaction with VEGFR-
1 [43]. This biological information was used as the main constraint for filtering and selecting the 
docked complex. Additionally, it is known that residues from both the VEGF dimers are 
involved in receptor binding interactions with VEGFR-1 and in order to bind competitively to 
VEGF and inhibit the phosphorylation of VEGFR-1, the interacting surface between the two 
proteins should be sufficiently large and involve all the key residues. This was not considered as 
a necessary criterion, but used only to rank complexes that matched both the criteria. The top 
ranked 100 complexes obtained from this filter were visually analyzed and the residues 
implicated by experimental results as having an influence on the interaction were used to guide 
the manual selection of final docked complex. A model structure for the docked complex was 
selected that was most compatible with the available experimental information. 
 
2.4. Molecular dynamics simulations 
 
The best structural model for the ternary complex of VEGF–SPARC obtained from the docking 
procedure was subjected to MD simulation to refine the protein interface. However, no explicit 
constraint functions were used to maintain the initial docking contacts during the simulation. The 
structures were first energy minimized using 1000 steps of steepest descent and 2000 steps of 
conjugate gradient minimization using the Kollman all-atom force field implemented in 
SYBYL [44]. A distance dependent dielectric function was used with the dielectric constant set 
to 1 and the nonbonded cutoff was set to 8 Å. Energy minimization with classical force field can 
be used to remove unrealistically close steric clashes and large deviations from ideal geometry 
resulting from the conformational changes of amino acid side chains after docking, but molecular 
dynamics simulation is required to improve rotamer distributions. This energy minimized 
structure was used as the starting structure for the MD simulation. All MD simulations were 
performed with the AMBER 7.0 molecular simulation package [45]. A 3 ns simulation was 
performed under constant pressure conditions using the parm99 force field to describe the 
interactions between the protein atoms [46]. As in the minimization, the dielectric constant was 
set to 1.0 was used and an 8 Å residue charge group based cutoff for nonbonded interactions was 
used, with the nonbonded pairlist updated every 15 steps. This cutoff was chosen to reduce the 
computational time involved due to the large size of the system. The bonds involving hydrogen 
atoms were constrained using SHAKE algorithm [47]. The simulation used a 2 fs time step for a 
total simulation time of 3 ns. The final conformation obtained at the end of the MD simulation 
was used for identifying specific interactions at the interface, computing inter-residue distances 
and other calculations. 
 
3. Results and discussion 
 
To be plausible, the complex structure of VEGF–SPARC derived from protein–protein docking 
simulation must be consistent with the available experimental information and also should reflect 
the nature of protein–protein interactions in general [48], [49]. Predicting protein–protein 
interactions is inherently challenging owing to the difficulty in modeling the many forces that 
contribute to these interactions [50]. This leaves the burden of excluding false positives from the 
docking results and ascertaining whether the model obtained is reliable by using accurate scoring 
and filtering techniques. Apart from using surface complementarity and electrostatic filter, 
residue pair potentials and biochemical data were also included to score the docking orientations, 
as it has been shown to produce more accurate results than using geometric fit and electrostatic 
energy alone [40]. The most favorable solution obtained by this method was then refined through 
molecular dynamics to get the final docked model (Fig. 3) which was used to analyze the 
interactions at the protein interface. 
 
 
Fig. 3. Cartoon representation of the structure of the VEGF–SPARC complex obtained through 
docking simulation: VEGF monomers are colored green and blue, while SPARC is colored red. 
 
3.1. Scoring and filtering the docked conformations 
 
In order to upgrade these models to reliable predictions, which could be used with confidence for 
further experimental and computational work, refinement using biological data is done. Any 
docking program attempting to find a complex structure for two given molecules based on 
surface complementarity and geometric fitting would invariably return several docking poses 
between the two molecules [51]. However, a large percentage of the docking orientations would 
be biologically irrelevant and can be easily eliminated through simple visual inspection, if some 
experimental information regarding their interaction is known. In this study, the presence of 
specific experimental information regarding the binding of SPARC to VEGF proved very useful 
as a means of filtering the docking results. To narrow down the list of possible orientations to 
include only biologically relevant structures, we paid attention to the experimental information 
that the binding of SPARC to VEGF is mediated specifically through the peptide 4.2 region of 
SPARC [32], [52], [53]. Additionally, we also took into account the hypothesis that the binding 
site of SPARC on VEGF should overlap, at least partially, the binding site of VEGFR-1. A 
distant constraint was therefore applied to filter the structures to include only the orientations 
where the peptide 4.2, comprising of amino acid residues 255–274, was within 4 Å distance from 
the VEGFR-1 binding site. Only the complex structures that correlated well with this 
experimental information were retained and the top 100 orientations were analyzed and 
compared with one another to select the final docked conformation. Apart from this biochemical 
data, the selection of the final model for the docked complex was also based on factors like the 
area of surface contact, extent of interactions present and stability of the model. This led to the 
model structure of the VEGF–SPARC complex (Fig. 3) in which there are several intermolecular 
hydrogen bonds between the two molecules, apart from hydrophobic and other long-range 
electrostatic interactions. 
 
3.2. Identification of side-chain interactions 
 
Long-range non-specific electrostatic interactions as well as short-range electrostatics like 
hydrogen bonds and salt bridges are crucial for complex stability [54]. To determine the mode of 
action, information about which amino acid residues come into contact when the complex is 
formed is important to supplement the data obtained from mutagenesis and other experimental 
methods. Also as mentioned above, the information on amino acid residues is also important to 
validate our working hypothesis of an overlapping binding site for SPARC and VEGFR-1, in 
order for SPARC to inhibit the VEGF-stimulated phosphorylation of VEGFR-1. Results from 
previous mutagenesis studies have shown specific regions in VEGF responsible for receptor 
binding interactions with VEGFR-1 and VEGFR-2 [43]. The region composed of predominantly 
acidic residues (aa 63–67) mediates binding to VEGFR-1 and another region composed of basic 
residues (aa 82–86) mediates binding to VEGFR-2. These oppositely charged surface regions are 
present at distal ends of the monomer, but since VEGF molecules exist as disulfide-linked 
homodimers these two regions are in close proximity in the dimeric form creating a cluster of 
receptor binding determinants at each end of the VEGF molecule (Fig. 4). Apart from this cluster 
of residues, the VEGFR-2 binding determinants form two other hot spots: Phe 17′ and Gln 79; 
and Ile 46, Glu 64′ and Ile 83′, which are present on the same face that is responsible for receptor 
binding in VEGF [55]. 
 
 
Fig. 4. VEGF receptor binding interactions; red solid representation corresponds to the acidic 
residues that mediate VEGFR-1 binding (aa 63–67) and blue solid representation corresponds to 
the basic residues that mediate VEGFR-2 binding (aa 82–86). 
 
Table 1. Residues at the interface responsible for hydrogen-bonding interactions (range 2.0–
3.2 Å) 
Chain 1 Position 1 Residue 1 Atom 1 Distance Atom 2 Residue 2 Position 2 Chain 2 
A 259 ASP OD1 2.66 NZ LYS 16 W 
A 259 ASP OD2 2.68 NZ LYS 16 W 
A 276 LYS NZ 2.86 OD1 ASP 63 W 
A 276 LYS NZ 2.76 OD2 ASP 63 W 
A 151 ARG NH1 3.20 OE1 GLN 89 V 
A 201 ARG NE 3.17 NE2 HIS 86 V 
A 204 GLU OE2 3.05 ND1 HIS 86 V 
A 258 LEU O 2.97 NE2 GLN 79 V 
A 272 CYS O 3.05 NE2 GLN 89 V 
Chain A denotes the SPARC molecule; chains V and W denote the VEGF dimers. 
 
Fig. 5. Amino acid residues involved in side-chain interactions at the VEGF–SPARC binding 
interface. Residues that stabilize complex formation include: Panel A, VEGF Asp 63 with 
SPARC Lys 276; Panel B, VEGF Gln 79 with SPARC Leu 258; Panel C, VEGF His 86 with 
SPARC Glu 204 and Arg 201. 
 
In our efforts to identify the key residues that drive the interaction between VEGF and SPARC 
and stabilize their complex, the side-chain interactions between the amino acids listed in Table 
1, Table 2, were identified as crucial for binding activity and these binding hot spots will be used 
to guide site-directed mutagenesis studies. 
 
Table 2. Residues at the interface responsible for hydrophobic interactions (range 2.0–3.8 Å) 
Chain 1 Position 1 Residue 1 Atom 1 Distance Atom 2 Residue 2 Position 2 Chain 2 
A 258 LEU CB 3.63 CD GLN 79 V 
A 258 LEU CD2 3.8 CD GLN 79 V 
A 258 LEU CA 3.58 CD GLN 79 V 
A 258 LEU C 3.65 CD GLN 79 V 
A 258 LEU CD2 2.6 CD1 ILE 91 V 
A 258 LEU CD2 3.4 CG2 ILE 91 V 
A 258 LEU CD2 3.58 CB ILE 91 V 
A 258 LEU CD2 2.64 CG1 ILE 91 V 
A 258 LEU CG 3.77 CD1 ILE 91 V 
A 271 GLY C 3.77 CE MET 81 V 
A 258 LEU CD1 3.09 CD2 PHE 17 W 
A 258 LEU CD1 2.31 CB PHE 17 W 
A 258 LEU CD1 2.86 CG PHE 17 W 
A 258 LEU CD1 3.62 CA PHE 17 W 
A 258 LEU CG 3.51 CB PHE 17 W 
A 277 GLN CD 3.78 CE MET 18 W 
Chain A denotes the SPARC molecule; chains V and W denote the VEGF dimers. 
 
The side-chain interactions involving these residues (Fig. 5) at the interface of VEGF and 
SPARC contribute a large fraction of binding free energy, highlighting their importance in 
stabilizing the protein complex. 
 
The hydrogen bonding interactions involving several key residues in the binding hot spots are 
consistent with our hypothesis that SPARC binds to VEGF on the same receptor binding face 
that mediates its interaction with VEGFR-1. The prevalence of several non-polar amino acids is 
a characteristic trait of docking interfaces [49]. 
 
3.3. Computational alanine scanning 
 
The role of individual amino acid side chains in stabilizing the complexes was further probed by 
computational alanine scanning studies, which identifies residues that are important for the 
stabilization of the complex, by determining the change in the free energy of binding when 
various residues in the wild type protein was mutated to alanine [56], [57]. The results from the 
alanine scanning experiments (Table 3, Table 4) correlated well with the docking simulation 
results. 
 
The experimental studies carried out previously showed that the peptide 4.2 region of SPARC 
inhibited VEGF-induced cell proliferation and the model of the VEGF–SPARC complex 
obtained from our docking studies showed that the residues in this region play a significant role 
in binding stability. The results from computational alanine scanning confirm that these residues 
are important for the stability of the complex. Positive values of ΔΔG means that the alanine 
mutation is predicted to destabilize the complex and negative values indicate a stabilizing effect. 
Computational mutation of Asp 63, Gln 79, His 86 and Gln 89 in VEGF as well as several 
residues in the region from 255 to 274 in SPARC, to alanine had unfavorable effects on the 
stability of the complex. This study indicates that the enthalpic contribution from the desolvation 
of amino acids, formation of novel H-bonds, van der Waals and electrostatic interactions 
involving these residues contribute to a favorable free energy of interaction between VEGF and 
SPARC, and offset the decrease in entropy from the loss of translational and rotational degrees 
of freedom upon binding. 
 
Table 3. Results of the predicted contributions of residues through virtual alanine scanning 
PDB # Chain Int_ID ΔΔG (bind) ΔG (partner) 
16 W 1 1.46 −0.21 
17 W 1 1.70 0.06 
21 W 1 1.97 −0.39 
63 W 1 1.24 −0.48 
258 A 1 1.70 0.74 
259 A 1 1.19 −0.77 
267 A 1 1.17 1.42 
276 A 1 1.15 −0.92 
Chain A denotes the SPARC molecule; chain W denotes the VEGF monomer. (Column 1) PDB#, number of 
mutated residue in the pdb file; (column 2) Chain, pdb chain identifier; (column 3) Int_ID, measure of whether a 
residue is interacting directly (1) or not interacting directly but is buried upon binding (0); (column 4) ΔΔG (bind), 
predicted change in binding free energy upon alanine mutation; (column 5) ΔG (partner), predicted change in 
protein stability of the mutated partner upon alanine mutation. 
 
Table 4. Results of the predicted contributions of residues through virtual alanine scanning 
PDB # Chain Int_ID ΔΔG (bind) ΔG (partner) 
148 A 1 1.25 2.16 
151 A 1 2.48 2.52 
255 A 1 1.63 0.20 
258 A 1 1.66 0.74 
272 A 1 1.01 5.33 
79 V 1 1.48 0.16 
86 V 1 1.08 −0.61 
89 V 1 4.03 −0.43 
90 V 1 1.67 −0.52 
91 V 1 0.96 0.94 
Chain A denotes the SPARC molecule; chain V denotes the VEGF monomer. (Column 1) PDB#, number of mutated 
residue in the pdb file; (column 2) Chain, pdb chain identifier; (column 3) Int_ID, measure of whether a residue is 
interacting directly (1) or not interacting directly but is buried upon binding (0); (column 4) ΔΔG (bind), predicted 
change in binding free energy upon alanine mutation; (column 5) ΔG (partner), predicted change in protein stability 
of the mutated partner upon alanine mutation. 
 
It is also interesting to note that several important hydrogen bonding and hydrophobic 
interactions observed in our proposed model for VEGF–SPARC complex, not only validate our 
hypothesis of an overlapping binding with VEGFR-1, but also indicate the possibility of an 
overlapping binding site with VEGFR-2, as several of the critical residues responsible for 
VEGFR-2 binding are involved in SPARC recognition as well. The hydrogen bonding 
interactions involving residues Gln 79 and His 86, and hydrophobic interactions involving 
residues Phe 17, Arg 82 and Ile 83 which are also crucial for VEGFR-2 binding strongly support 
the involvement of the same hot spot residues on the VEGF surface, in mediating its interaction 
with the receptors as well as with molecules such as SPARC. The current model is consistent 
with known evidence of SPARC inhibition of VEGFR-1 activation [58] and agrees well with the 
experimental data that the region of residues 255–274 in SPARC possess anti-angiogenic 
functions through its binding with VEGF [32]. While the present docking model supports a non-
selective inhibition of the activity of VEGF receptors, it does not explain the results from a 
previous study which found that SPARC did not inhibit VEGF-mediated activation of VEGFR-
2 [32]. In any case, further studies using site-directed mutagenesis and other experimental 
methods will be required to verify the binding sites identified by our docking model. 
 
4. Conclusions 
 
In the current study, we have demonstrated the application of protein–protein docking simulation 
to build a complex structure of VEGF–SPARC starting from unbound proteins using the 
program FTDock. This work is based on the premises that, (1) starting from unbound structures, 
computer docking simulation can be used to build a set of atomic models of complexes, one of 
which will be close to the native complex structure, and (2) by applying proper filtering and 
scoring methods, it is possible to select the “correct” structure from the docking results. We have 
used electrostatics, residue pair potentials and biochemical information to filter and rank the 
docked models and build a reliable model of the complex structure. After filtering, the final 
model of the complex was selected that agreed best with the biological data and it was refined 
using molecular dynamics, to analyze the interactions and identify hot spot residues. These hot 
spots at the protein–protein interface, which are small regions that are crucial to binding, can be 
targeted by small molecules to mimic the protein–protein interactions. Thus, by combining 
biological information with computational docking, we have been able to put forward a model in 
which SPARC binds to VEGF near its VEGFR-1 binding domain. This model can be used for 
future experimental and computational studies to draw biological and functional conclusions. 
Using site-directed mutagenesis, to be carried out based on the interactions identified in this 
study, it should be possible to confirm the predicted mode of SPARC binding to VEGF. 
Knowledge of the interactions and important binding residues at the protein interface will enable 
new strategies to target VEGF and inhibit angiogenesis. 
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